Abstract 466P
Background
The daycare caters to numerous cancer patients. Patient satisfaction is a surrogate estimator of the quality of healthcare. Determination of the factors responsible for this will help to improve patient care delivery.
Methods
Women with breast or ovarian malignancies undergoing chemotherapy at the medical oncology daycare unit from 1st January 2023 to 1st April 2023 were invited to complete the PSS questionnaire anonymously. The PSS tool is an abbreviated 28 item questionnaire related to administrative services, medical team members and the treating consultant. The response options comprised a 5-point Likert scale. The raw scores were linearly transformed to a 0-100 scale and patients scoring more than 60 were considered as satisfied.
Results
A total of 117 patients participated in the study. There was a high level of overall satisfaction rate (93.2%). Availability of social support and health insurance were significant determinants of patient satisfaction (p=0.0043 and p=0.0006 respectively). The median waiting time was 3 hours with a satisfaction rate of 84%. The satisfaction rate for secretarial assistance, medical staff and the treating physician were 94%, 94% and 93.2% respectively. The patients’ likelihood of returning to our daycare for and recommending it to others were 97.4% and 96.6% respectively.
Conclusions
Ensuring availability of social support, provision of health insurance and effective patient-physician communication is likely to increase patient satisfaction.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract